Horm Metab Res 2009; 41(10): 757-761
DOI: 10.1055/s-0029-1225363
Animals, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

In Vivo Knockdown of p85α with an Antisense Oligonucleotide Improves Insulin Sensitivity in Lep ob/ob and Diet-induced Obese Mice

M. W. Moriarty1 , C. E. McCurdy1 , R. C. Janssen1 , T. Shaw1 , J. W. Leitner2 , J. E. Friedman1 , 3 , B. Draznin2
  • 1Department of Pediatrics, University of Colorado Denver, Aurora, CO, USA
  • 2Department of Medicine, University of Colorado Denver, Aurora, CO, USA
  • 3Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO, USA
Further Information

Publication History

received 05.03.2009

accepted 27.05.2009

Publication Date:
13 July 2009 (online)

Abstract

Phosphoinositide 3-kinase is a key signaling intermediate necessary for the metabolic actions of insulin. In this study, we assessed the effects of in vivo knockdown of the p85α subunit of phosphoinositide 3-kinase on insulin sensitivity, using an antisense oligonucleotide, in lean mice, diet-induced obese mice, and obese leptin-deficient Lep ob/ob mice. Mice were injected with either p85α-targeted antisense oligonucleotide or saline twice weekly for 4 weeks. Fasting levels of glycemia and insulinemia and insulin and glucose tolerance tests were used to determine insulin sensitivity. Western blot analysis and real-time polyacrylamide chain reaction were used to assess p85α protein and mRNA expression. In vivo administration of antisense oligonucleotide resulted in 50 and 60% knockdown of liver p85α protein and mRNA, respectively, in the lean, diet-induced obese and Lep ob/ob mice. This was associated with increased phosphoinositide 3-kinase activity and improved insulin sensitivity in diet-induced obese and Lep ob/ob mice. Thus, p85α could be an important therapeutic target to ameliorate insulin resistance.

References

  • 1 Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.  Biochem J. 1998;  333 471-490 , [Erratum: Biochem J 1998; 3 35 (Pt 3): 711]
  • 2 Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.  J Clin Invest. 1999;  103 931-943
  • 3 Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.  Mol Cell Biol. 2002;  22 965-977
  • 4 Giorgino F, Pedrini MT, Matera L, Smith RJ. Specific increase in p85alpha expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells.  J Biol Chem. 1997;  272 7455-7463
  • 5 Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes.  J Clin Invest. 2002;  109 141-149
  • 6 Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, Okuno A, Inukai K, Asano T, Kaburagi Y, Ueki K, Nakajima H, Hanafusa T, Matsuzawa Y, Sekihara H, Yin Y, Barrett JC, Oda H, Ishikawa T, Akanuma Y, Komuro I, Suzuki M, Yamamura K, Kodama T, Suzuki H, Yamamura K, Kodama T, Suzuki H, Koyasu S, Aizawa S, Tobe K, Fukui Y, Yazaki Y, Kadowaki T. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.  Nature Genet. 1999;  21 230-235
  • 7 Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.  Mol Cell Biol. 2000;  20 8035-8046
  • 8 Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling.  J Biol Chem. 2003;  278 48453-48466
  • 9 Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 Expression and Decreased Phosphotidylinositol 3-Kinase Activity in Insulin-Resistant Human Skeletal Muscle.  Diabetes. 2005;  54 2351-2359
  • 10 Friedman JE, Ishizuka T, Shao J, Huston L, Highman T, Catalano P. Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes.  Diabetes. 1999;  48 1807-1814
  • 11 Cornier MA, Bessesen DH, Gurevich I, Leitner JW, Draznin B. Nutritional upregulation of p85alpha expression is an early molecular manifestation of insulin resistance.  Diabetologia. 2006;  49 748-754
  • 12 Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, Kopchick JJ, Friedman JE, Draznin B, Thorner MO. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.  Diabetes. 2007;  56 1638-1646
  • 13 Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.  Proc Natl Acad Sci USA. 2002;  99 419-424
  • 14 Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.  J Biol Chem. 2007;  282 22678-22688
  • 15 Yu XX, Murray SF, Watts L, Booten SL, Tokorcheck J, Monia BP, Bhanot S. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.  Am J Physiol Endocrinol Metab. 2008;  295 E436-E445
  • 16 Yu XX, Pandey SK, Booten SL, Murray SF, Monia BP, Bhanot S. Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression.  Am J Physiol Endocrinol Metab. 2008;  294 E530-E539
  • 17 Dean NM, Butler M, Monia BP, Manoharan M. Pharmacology of 2′-O-(2-methoxy)ethyl-modified antisense oligonucleotide. In: Crooke ST (ed). Antisense Drug Technology: Principles, Strategies and Applications. New York: Dekker 2001: 319-338
  • 18 Pandey SK, Yu XX, Watts LM, Michael MD, Sloop KW, Rivard AR, Leedom TA, Manchem VP, Samadzadeh L, McKay RA, Monia BP, Bhanot S. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.  J Biol Chem. 2007;  282 14291-14299
  • 19 Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, Herrine S, Hoofnagle J, Liang TJ, Rehermann B. Effects of antiviral therapy on the cellular immune response in acute hepatitis C.  Hepatology. 2004;  40 87-97
  • 20 Barbour LA, Mizanoor RS, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.  J Biol Chem. 2005;  280 37489-37494
  • 21 Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin.  Diabetes. 2006;  55 2392-2397
  • 22 Li P, Koike T, Qin B, Kubota M, Kawata Y, Jia YJ, Oshida Y. A high-fructose diet impairs Akt and PKCζ phophorylation and GLUT4 translocation in rat skeletal muscle.  Horm Met Res. 2008;  40 528-532

Correspondence

M. W. MoriartyMD 

The Children's Hospital

13123 E. 16th Ave., B265

Aurora

CO 80045

USA

Phone: +1/720/777 61 28

Fax: +1/720/777 73 01

Email: Megan.Moriarty@ucdenver.edu

    >